DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Fabrice André, Komal Jhaveri, José Luiz Pedrini et al.|Journal of Clinical Oncology|2024Cited by 32
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).Fabrice André, Komal Jhaveri, Erika Hamilton et al.|Journal of Clinical Oncology|2022Cited by 25
Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)Erika Hamilton, Fabrice André, Komal Jhaveri et al.|Cancer Research|2023Cited by 5